Claudia Monaco is a Professor of Cardiovascular Inflammation at the Kennedy Institute of Rheumatology, University of Oxford . Her research focuses on the intersection of inflammation and cardiovascular diseases, particularly atherosclerosis. Institution: University of Oxford Department: Cardiovascular Research Academic Rank: Professor Her work investigates molecular mechanisms in atherosclerosis, including roles of interferon regulatory factors , matrix metalloproteinases , and immunotherapy . Recent publications highlight advancements in spatial transcriptomics and aging-related cardiovascular interventions. Collaborative studies explore TGF-β2 activation in diabetic atherosclerosis and inflammatory regulation by B regulatory cells . Her lab employs proteomic profiling to identify disease-specific biomarkers in smooth muscle cells.
Dr. Stephen Sansom serves as Associate Professor and Group Leader of the Computational and Single Cell Genomics Group at the University of Oxford's Kennedy Institute. His work bridges computational biology with immunology to decode inflammatory disease mechanisms through advanced genomic approaches. His academic foundation includes a BSc (Hons) in Biochemistry from the University of Dundee (2001) followed by a DPhil in Developmental Biology through the Wellcome Trust 4-year PhD programme at the University of Cambridge. Postdoctoral research at the Gurdon Institute with Dr. Rick Livesey established his expertise in genomic analysis of neural development. Dr. Sansom's research centers on computational genomics of immune processes, particularly central tolerance mechanisms and inflammatory disorders. His group pioneers single-cell genomic methodologies to dissect cellular heterogeneity in conditions like inflammatory bowel disease, rheumatoid arthritis, and atherosclerosis. Key innovations include developing frameworks for analyzing promiscuous gene expression in thymic epithelia and deconvoluting monocyte responses in immune-mediated diseases through collaborative projects with experimental immunologists. Analysis of his recent publications reveals dominant themes in macrophage biology during atherosclerosis progression, B/T cell dynamics in viral infections (including influenza and COVID-19), and stromal cell contributions to joint destruction in arthritis. His work consistently identifies novel cellular states and molecular networks driving pathogenesis, with strong emphasis on translational relevance for therapeutic targeting. Supported initially by an MRC Career Development Fellowship in Chris Ponting's CGAT program, Dr. Sansom now directs the Computational Genomics team he established at the Kennedy Institute in 2014. His collaborative model integrates computational expertise with wet-lab immunology across multiple Oxford research groups. The Sansom Group operates as the Computational and Single Cell Genomics Group within the Kennedy Institute, maintaining specialized pipelines for high-dimensional genomic data analysis. Current efforts focus on scaling single-cell multi-omics approaches to track immune cell evolution during chronic inflammation and infection.
Philip K. Hopke, Ph.D., serves as an Adjunct Professor in both the Department of Public Health Sciences and Department of Environmental Medicine at the University of Rochester School of Medicine and Dentistry. With a distinguished career spanning over five decades since earning his Ph.D. from Princeton University in 1969, Dr. Hopke has established himself as a global leader in environmental chemistry and air pollution research. Ph.D. in Chemistry, Princeton University (1969) M.A. in Chemistry, Princeton University (1967) B.S. in Chemistry, Trinity College (1965) Dr. Hopke's pioneering work focuses on particulate matter source apportionment , where he developed innovative methodologies like dispersion-normalized positive matrix factorization (DN-PMF). His research integrates chemometrics , atmospheric chemistry , and environmental epidemiology to address critical air quality challenges worldwide. Recent projects span China's megacities, Iran's water crisis, and New York State's vehicle emission regulations, with particular emphasis on health impacts of source-specific pollutants. Analysis of his 15 most recent publications reveals consistent focus on advanced source apportionment techniques , health outcomes linked to air pollution , and policy evaluation using sophisticated statistical modeling. His work increasingly incorporates machine learning approaches while maintaining rigorous chemical characterization of environmental samples. Scientific Recognition Fellow of both the Air and Waste Management Association (2021) and American Association for Aerosol Research Recipient of the Lifetime Achievement Award in Chemometrics (2014) Albert Nelson Marquis Lifetime Achievement Inductee (2018) Multiple international awards including the Fissan-Pui TSI International Aerosol Research Award (2018) Dr. Hopke maintains an exceptionally active research program with collaborators across six continents, evidenced by his 2025 publications from China, Iran, Kazakhstan, and the United States. His work bridges fundamental atmospheric science with practical public health applications, particularly in evaluating regulatory impacts on air quality and health outcomes.
Dr. Najib Ayas is an Associate Professor in the Division of Critical Care Medicine, Department of Medicine, Faculty of Medicine at the University of British Columbia. He graduated with distinction from the University of Alberta in 1992, completed Internal Medicine residency at the Mayo Clinic in 1996, and postgraduate training in Respiratory, Critical Care, and Sleep Medicine at Brigham and Women's Hospital/Harvard Medical School in 2000. He joined the Sleep Disorders Program at UBC in September 2002 and has maintained an active academic career since. Dr. Ayas received his undergraduate education at the University of Alberta (General Science, 1986-1988), followed by his MD (1988-1992). He completed a Rotating Internship at St Thomas Medical Center in Akron, Ohio (1992-1993), Internal Medicine Residency at Mayo Graduate School of Medicine in Rochester, MN (1993-1996), Pulmonary & Critical Care Fellowship at Harvard (1996-2000), and a Master of Public Health from Harvard School of Public Health (2000-2002). Dr. Ayas's primary research focus centers on the public health and safety consequences of sleep apnea and sleep deprivation. His work spans multiple domains including cardiovascular consequences of sleep disorders, epidemiology of obstructive sleep apnea, development of diagnostic tools, and cost-effectiveness of treatments. He has made significant contributions to understanding how sleep disorders affect occupational safety, cardiovascular health, and overall quality of life. His research often involves interdisciplinary collaborations across sleep medicine, critical care, public health, and epidemiology. Analysis of Dr. Ayas's recent publications reveals a strong focus on obstructive sleep apnea (OSA), particularly its cardiovascular consequences, diagnostic approaches, and treatment effectiveness. His work spans basic science investigating mechanisms like intermittent hypoxia effects on endothelial function, to clinical trials examining CPAP therapy, to large epidemiological studies on OSA prevalence and impact. A notable trend is his increasing focus on special populations including patients with spinal cord injuries, pregnant women, and those with comorbid conditions like COPD. His research maintains a strong translational emphasis, bridging laboratory findings to clinical applications. BC Lung Association Career Development Award (2002) New Investigator Salary Award, CIHR/BC Lung Association Award (2002-2007) Scholar Award, Michael Smith Foundation (2004-2009) Established Clinician Scholar Award, VCHRI (2009-2012) Award for Clinical Teaching Excellence, Division of Critical Care Medicine UBC (2013) Martin Hoffman Award Excellence in Research As an educator, Dr. Ayas has supervised numerous graduate students including Masters candidates, Doctoral students, and Post-doctoral fellows. His students have pursued research in areas including sleep apnea pathophysiology, cardiovascular consequences of sleep disorders, and clinical applications of sleep medicine. Dr. Ayas has served on multiple grant review panels for organizations including CIHR, Canadian Lung Association, and Michael Smith Foundation, contributing to the evaluation and funding of critical research in respiratory and sleep medicine. He has directed the Respiratory Physiology course (MED560/Path518) at UBC since 2006 and has been instrumental in developing clinical guidelines including the Canadian Thoracic Society and Canadian Sleep Society position paper on obstructive sleep apnea and driving.
James Millonig is an Associate Professor in the Department of Neuroscience and Cell Biology at Rutgers University, where he also serves as the Senior Associate Dean for the Rutgers School of Graduate Studies. He is affiliated with the Center for Advanced Biotechnology and Medicine (CABM) and Robert Wood Johnson Medical School. His research focuses on understanding dorsal central nervous system (CNS) development, particularly through the integration of mouse genetics with neuroanatomy. His lab investigates how signaling centers like the roof plate coordinate CNS development through secreted factors such as Bone Morphogenetic Proteins (BMPs). A significant portion of his work examines the role of transcription factors like Lmx1a and Engrailed-2 in neural development and their potential connections to autism spectrum disorder (ASD). Dr. Millonig's recent publications demonstrate a continued focus on neurodevelopmental disorders, particularly autism spectrum disorder. His work spans from basic developmental neuroscience examining dorsal CNS formation to translational research using patient-derived neural progenitor cells. His laboratory has made significant contributions to understanding how genetic variations affect early brain development in ASD, with recent studies analyzing brain stem cells from ASD patients to identify irregularities in very early brain development. Autism Research Program (ARP) Idea Development Award from Department of Defense (2022) Standing appointment as a member of the National Institute of General Medical Sciences (NIGMS) Training and Workforce Development Subcommittee C (2020) Dr. Millonig has secured multiple federal grants, including an ongoing project titled "Investigation of Professional Coaching as an Intervention to Support the Success of URG Biomedical Ph.D. Students" (2023-2026) funded by the National Institute of General Medical Sciences. He has served as Principal Investigator for projects including "A Mouse Knock-In Model for ENGRAILED 2 Autism Susceptibility" funded by the National Institute of Mental Health and has been Co-Principal Investigator on the "IMSD at Rutgers - New Brunswick" project. The Millonig Lab maintains an active research program with several graduate students and research associates. Current lab members include Stuart Cattel (Graduate Student) and Arif S W Kusuma (Graduate Fellow), with Paul Matteson serving as Research Associate I. The lab has previously trained Marcos Ayala-Rivera, Tomas Kasza, and Monal Mehta, demonstrating a strong commitment to mentoring the next generation of scientists in neuroscience and developmental biology.
Mahmut Esat Uzun serves as an Assistant Professor in the Department of Coaching Education at Karabük University's Hasan Doğan Faculty of Sports Sciences since 2023, specializing in Training Science and Exercise Physiology. His research examines physiological responses to diverse exercise interventions across multiple athletic populations. His academic background includes: Doctorate in Coach Education from Selçuk University (2019) Master's in Physical Education and Sports (Thesis) from Selçuk University (2017) Bachelor's in Sports Management from Selçuk University (2011) Uzun's research focuses on experimental analysis of exercise modalities including Zumba, Tabata, and sport-specific training protocols. His work investigates physiological adaptations in sedentary populations, elite wrestlers, football players, and adolescent athletes, with particular attention to hormonal responses, physical fitness components, and pandemic-era exercise constraints. Current projects explore warm-up optimization for football performance and neuromuscular adaptations in combat sports. His 8 journal articles (2020-2025) demonstrate evolving expertise from foundational studies on balance abilities and table tennis risk assessment toward contemporary research on warm-up protocols and pandemic exercise adaptations. Collaborative patterns reveal strong institutional ties with Karabük University colleagues, particularly in applied sports physiology research. No scientific awards or recognitions have been documented in available records. Uzun has no recorded thesis advisement and no public information regarding research grants. His publication record suggests independent research leadership with frequent co-authorship on experimental studies rather than large-scale funded projects. No specific laboratory facilities or dedicated research teams are mentioned in available documentation, though his work consistently involves collaborative research groups within Karabük University's sports science department.
Eva Swinnen is a researcher at the Vrije Universiteit Brussel within the Brubotics Rehabilitation Research Center, focusing on physiotherapy, human physiology, and anatomy. Her work bridges robotics and rehabilitation medicine. Key research areas: Walking (100%), Gait Analysis (86%), Systematic Reviews (59%), Orthotic Devices (51%) Recent Publications (2025): Explore AI applications in stroke rehabilitation, virtual twin technology, and electrotherapy effects on muscle recovery. Notable collaborations include projects with KU Leuven and Radboud University Medical Center. 2022 Kuka Innovation Award Finalist 2019 Phase I & II App Development Competition Winner Supervision: Guided master's theses on topics like Kinect™ system validation, volleyball spike biomechanics, and EMG patterning in motor tasks. Currently involved in EU-funded TARGET consortium initiatives for stroke management.
Dr. Katrin J Svensson is an Associate Professor of Pathology at Stanford University and Affinity Group Leader at the Stanford Diabetes Research Center. She received her Ph.D. from Lund University (2012) and completed postdoctoral training at Harvard Medical School/Dana-Farber Cancer Institute (2017). Her research focuses on discovering circulating factors and peptide hormones that regulate metabolism through computational, proteomic, and physiological approaches. Key discoveries: Isthmin-1 (glucose/lipid homeostasis), BRINP2-related peptide (anti-obesity effects), ANGPTL3 (fructose metabolism) Academic Affiliations: Bio-X, Cardiovascular Institute, Wu Tsai Human Performance Alliance, MCHRI Faculty Fellow Research Highlights: Mapping tissue-specific peptide secretion to identify orphan ligands Characterizing receptors like GPR151 for glucose regulation Developing mitochondria-targeted therapies for cancer and metabolic diseases Investigating dietary sugar impacts on systemic metabolism Scientific Awards: Churg Research Award (2019) McCormick and Gabilan Award (2018) NIH K99/R00 Pathway to Independence Award (2016-2021) SRC International Postdoctoral Fellowship (2013-2016) Teaching & Mentorship: Leads Advanced Cell Biology courses (BIO 214/BIOC 224/MCP 221) and mentors graduate students/postdoctoral researchers in Biochemistry, Biophysics, and Cancer Biology programs.
Professor Alain de Bruin (born 1968) is a distinguished academic at Utrecht University, serving as Professor in the Department of Biomolecular Health Sciences within the Faculty of Veterinary Medicine. Since January 1, 2020, he has been Head of the Department of Biomolecular Health Sciences. His academic journey began with veterinary medicine studies at the University of Hannover in Germany, followed by a PhD from the University of Bern in Switzerland in 1999. After specializing in veterinary pathology and completing a postdoctoral position at Ohio State University, he was appointed professor of pathobiology at Utrecht University in 2005. In 2010, he founded the Netherlands Molecular Pathology Center (UU/UMCG) and became an honorary professor of molecular pathology at the University of Groningen in 2014. Professor de Bruin's research primarily focuses on cancer biology, liver pathology, tumor suppression mechanisms, and aging processes. His expertise includes in vivo modeling, cell cycle analysis, generating transgenic mouse models, pathological analysis of animal disease models, and single-cell transcriptomics. His work centers on proteins that regulate cell proliferation, particularly E2F transcription factors, which he has discovered play critical roles in inhibiting cancer cell growth. His research themes span Life Sciences, Regenerative Medicine, and the Utrecht Platform for Organoid Technology. Analysis of his recent publications reveals a consistent research trajectory centered on cell cycle regulation, particularly the atypical E2F transcription factors (E2F7 and E2F8), and their roles in cancer development, polyploidization, and liver disease. His work demonstrates how these factors influence tumor suppression, angiogenesis, and cellular responses to DNA damage. The publications span multiple disciplines including cancer biology, molecular oncology, hepatology, and regenerative medicine, with applications in both human and veterinary medicine. Professor de Bruin has held significant leadership positions, including chairing the research council (2017-2019) and coordinating the 'Regenerative Medicine, Stem Cells, and Cancer' research program (2013-2019). He serves on the editorial board of 'Frontiers in Cell and Developmental Biology' and participates in review committees for NWO-Rubicon/Veni, the research alliance UTwente/UU/UMCU, and the Comprehensive Cancer Center at Ohio State University. His laboratory work has made significant contributions to understanding how E2F transcription factors regulate cell proliferation, with implications for developing novel cancer therapy strategies. His research on polyploidization mechanisms has provided insights into liver regeneration and tumor development, while his work on senescence has implications for aging-related diseases.
Louise Pilote, MD, MPH, PhD is Professor of Medicine in the Department of Medicine, Division of Internal Medicine , McGill University , and Senior Scientist in the Cardiovascular Health Across the Lifespan Program at the Research Institute of the McGill University Health Centre (RI-MUHC) , Montréal, Canada. Education: Louise Pilote holds the combined degrees of MD, MPH, and PhD, reflecting advanced clinical, public-health and research training that underpins her translational work. Research Focus: Internationally recognized pioneer in sex- and gender-based cardiovascular epidemiology , developing novel gender indices to disentangle biological (sex) and sociocultural (gender) determinants of cardiovascular outcomes. Leads the multinational GOING-FWD consortium (Gender Outcomes International Group to Further Well-being Development), integrating sex/gender analytics across 30 cohorts totaling 30 million patients with chronic diseases. Authority on comparative effectiveness and pharmacoepidemiology leveraging administrative “Big Data”, clinical registries, and advanced biostatistical/machine-learning methodologies. Current clinical-translational projects include imaging-based diagnosis of coronary microvascular dysfunction , a condition disproportionately affecting women. Scientific Impact & Awards: While formal awards are not enumerated in the supplied text, Dr Pilote’s sustained leadership as senior author on major Canadian and international cardiovascular guidelines, her role in founding the GOING-FWD network, and her extensive publication record (398 PubMed-indexed articles, 1988-2025) collectively constitute significant peer recognition. Students & Mentoring: Specific trainee names are not provided in the text; however, as Professor at McGill and Senior Scientist at RI-MUHC she supervises graduate students, clinical research fellows, and post-doctoral researchers in cardiovascular epidemiology, data science, and gender medicine. Laboratories & Teams: Dr Pilote heads the cardiovascular epidemiology research group within the Centre for Outcomes Research and Evaluation (CORE) at RI-MUHC, coordinating a multi-disciplinary team of biostatisticians, data scientists, clinician-scientists, and trainees.
Dr. Stella Daskalopoulou is a Senior Scientist at the Research Institute of the McGill University Health Centre (RI-MUHC) and a Professor in the Department of Medicine at McGill University's Faculty of Medicine and Health Sciences. She specializes in translational cardiovascular research with a focus on vascular health, atherosclerosis, and hypertension management. Senior Scientist, RI-MUHC Glen site Professor, Department of Medicine, McGill University Member, Cardiovascular Health Across the Lifespan Program Research Focus: Her work integrates biomedical technology with clinical investigation to identify early vascular impairment markers. Key areas include: Arterial stiffness and hemodynamic assessment Adiponectin signaling pathways in atherosclerosis Sex-specific cardiovascular risk stratification Biomarker discovery for plaque instability Pregnancy-related vascular complications Machine learning applications in plaque classification Scientific Engagement: Dr. Daskalopoulou contributes to hypertension guideline development (2024 ESC Guidelines) and explores environmental impacts on vascular health (household pollution studies). Her recent publications emphasize: Deep learning for plaque characterization Sex hormone receptor pathways in atherosclerosis Adipokine interactions with HDL metabolism Clinical decision tools for preeclampsia prediction Laboratory: Leads the Vascular Health Unit at RI-MUHC, combining histopathology, immunophenotyping, and advanced imaging for translational research.
Dr. Jun-Li Liu is an Associate Professor in the Department of Medicine, Faculty of Medicine and Health Sciences at McGill University, and a Scientist at the Research Institute of the McGill University Health Centre (RI-MUHC) at the Glen site. She is affiliated with the Metabolic Disorders and Complications Program within the Centre for Translational Biology, focusing on diabetes research and pancreatic islet biology. Dr. Liu's educational background includes: BSc in Biology from Peking University, China (1978-1982) MSc in Physiology from Peking University Health Science Centre, China (1982-1985) PhD in Experimental Medicine from McGill University, Montreal, Canada (1990-1995) Postdoctoral fellowship at the National Institutes of Health, NIDDK, Bethesda, MD (1995-2000) Dr. Liu's research focuses on exploring novel growth factors that can be used to expand or preserve islet beta cells, which produce insulin, to prevent or treat diabetes mellitus. Her current work centers on CCN5/WISP2 and Reg family proteins normally produced in the pancreas, which have shown promise in rodent models of diabetes. Her laboratory investigates how these proteins promote beta-cell proliferation, survival, and regeneration through mechanisms including activation of signaling molecules like Akt and Erk1/2 kinases. The ultimate goal is to develop novel therapeutic approaches for diabetes treatment by exploiting these growth factors and their molecular targets. Her recent publications demonstrate a consistent focus on pancreatic islet biology, with particular emphasis on CCN5/WISP2 and Reg family proteins. These works span molecular mechanisms of beta-cell growth and survival, connections to diabetes pathogenesis, and potential translational applications. A significant theme across her work is understanding how growth factors might be harnessed for diabetes therapy, with implications for both type 1 and type 2 diabetes. Dr. Liu has received numerous scientific awards and recognitions throughout her career: Fellowship award from Medical Research Council of Canada (1996-1999) New Investigator Award from The Endocrine Society (1998) Fellows Award for Research Excellence from NIH (1999) Career Development Award from Juvenile Diabetes Research Foundation International (2000-2005) Travel Grant Award from The Endocrine Society (2001) John R. & Clara M. Fraser Memorial Award from McGill University (2005-2008) Chercheurs boursiers Fondamental, Senior, from Fonds de la recherché en santé Quebec (2008-2011) Dr. Liu has served on the editorial boards of the Journal of Diabetes (Blackwell Publishing) since 2008 and the Canadian Journal of Diabetes since 2017. She is also a member of the Montreal Diabetes Research Centre. Her research has been supported by various funding agencies, including the Juvenile Diabetes Research Foundation International and the Medical Research Council of Canada. She has mentored numerous graduate students and postdoctoral fellows in her laboratory. Dr. Liu leads a research laboratory at the RI-MUHC focused on pancreatic islet biology and diabetes research. Her team employs molecular, cellular, and in vivo approaches using transgenic and knockout mouse models to investigate the mechanisms by which growth factors regulate beta-cell mass and function. Current projects include studying CCN5/WISP2 and Reg family proteins in beta-cell proliferation, survival, and regeneration, with implications for diabetes therapy. They also investigate the role of Reg proteins in pancreatic ductal adenocarcinoma, exploring their potential as diagnostic markers and therapeutic targets.
Jason Shahin is an Assistant Professor at the Department of Medicine , Faculty of Medicine and Health Sciences , McGill University . He serves as an Investigator at the Research Institute of the McGill University Health Centre (RI-MUHC) , specifically within the Translational Research in Respiratory Diseases Program . His academic and clinical work bridges critical care medicine and respiratory medicine at the McGill University Health Centre (MUHC) . Research Focus: Dr. Shahin specializes in risk prediction in intensive care units (ICU) , with particular emphasis on prediction tools for complex populations , including the chronic critically ill and potential organ donors . His work integrates clinical data science with translational approaches to improve ICU outcomes. Article Trends: His publications span critical care medicine , sepsis , mechanical ventilation , and organ donation . Recent studies focus on machine learning applications , probiotics in infection prevention , and blood conservation strategies in ICU settings. Key Collaborations: He contributes to large-scale trials like the LOVIT , PROSPECT , and FORECAST studies, collaborating with networks such as the Canadian Critical Care Trials Group and REVA Network .
Dr. Wolfgang Hübner is a Researcher at the Faculty of Physics at University of Bielefeld, Germany, affiliated with the Biomolecular Photonics Group. His work focuses on advanced optical imaging techniques applied to cellular and molecular structures. He maintains an active research program as evidenced by numerous publications from 2023-2025. His research interests center on photonics, biophotonics, optical microscopy, super-resolution imaging techniques, cellular biophysics, and molecular imaging. Dr. Hübner's work bridges physics and biology, developing and applying cutting-edge microscopy methods to address biological questions at the nanoscale level. His recent publications demonstrate a strong focus on super-resolution microscopy techniques, particularly structured illumination microscopy, fluorescence lifetime imaging, and correlative imaging approaches. His research investigates cellular structures like liver sinusoidal endothelial cells, dystroglycan mutants, and mitochondrial dynamics, revealing how advanced optical methods can visualize biological processes at unprecedented resolution. Dr. Hübner's research shows consistent development in both methodological advances in optical imaging and biological applications. His work spans from fundamental optical engineering to biomedical applications, demonstrating interdisciplinary expertise across physics, engineering, and cell biology.
Professor Mark Dershwitz is affiliated with the UMass Chan Medical School under the T.H. Chan School of Medicine , specifically the Department of Anesthesiology and Perioperative Medicine . He holds a PhD in Pharmacology (1982) and an MD (1982), both from Northwestern University , with postdoctoral training in anesthesiology at Massachusetts General Hospital (1984-88). His research focuses on the pharmacokinetics (PK) and pharmacodynamics (PD) of intravenous anesthetics , particularly remifentanil and morphine . He pioneered studies on remifentanil’s esterase-mediated metabolism, demonstrating its consistent short duration even in patients with hepatic or renal failure . His work on postoperative nausea and vomiting (PONV) includes the first dose-response analysis of ondansetron and a safety reevaluation of droperidol , challenging its boxed warning. Recent articles highlight his expertise in anesthetic pharmacology , with trends in AI applications in medical education (e.g., ChatGPT-4 in board exams), opioid-PONV interactions , and clinical trial design involving human volunteers. His scientific awards include the 2017 Lamar Soutter Award for Excellence in Medical Education Multiple Outstanding Medical Educator Awards (2002-2016) 2001 Distinguished Alumnus Award from Oakland University
